

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/508,959
				Filing Date	August 16, 2005
				First Named Inventor	Chaim GILON et al
				Group Art Unit	1656
				Examiner Name	DESAI, ANAND U
Sheet	1	Of	3	Attorney Docket Number	28557
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	1	Uherek et al. "DNA-Carrier Proteins for Targeted Gene Delivery", Advanced Drug Delivery Reviews, 44: 153-166, 2000.			
	2	Fender et al. "Adenovirus Dodecahedron, A New Vector for Human Gene Transfer", Nature Biotechnology, 15: 52-56, 1997.			
	3	Johnson-Saliba et al. "Distinct Importin Recognition Properties of Histones and Chromatin Assembly Factors", FEBS Letters, 467: 169-174, 2000.			
	4	Luger et al. "Crystal Structure of the Nucleosome Core Particle at 2.8 Å Resolution", Nature, 389: 251-260, 1997.			
	5	Balicki et al. "Histone H2A-Mediated Transient Cytokine Gene Delivery Induces Efficient Antitumor Responses in Murine Neuroblastoma", Proc. Natl. Acad. Sci. USA, 97(21): 11500-11504, 2000.			
	6	Gari?py et al. "Vectorial Delivery of Macromolecules Into Cells Using Peptide-Based Vehicles", Trends in Biotechnology, 19(1): 21-28, 2001.			
	7	Kuismanen et al. "Low Temperature-Induced Transport Blocks as Tools to Manipulate Membrane Traffic", Methods in Cell Biology, 32: 257-274, 1989.			
	8	Vives et al. "Effects of the Tat Basic Domain on Human Immunodeficiency Virus Type 1 Transactivation, Using Chemically Synthesized Tat Protein and Tat Peptides", Journal of Virology, 68(5): 3343-3353, 1994.			
	9	Viv?s et al. "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates Through the Plasma Membrane and Accumulates in the Cell Nucleus", The Journal of Biological Chemistry, 272(25): 16010-16017, 1997.			
	10	Luger et al. "Expression and Purification of Recombinant Histones and Nucleosome Reconstitution", Methods in Molecular Biology: Chromatin Protocols, 119: 1-16, 1999.			
	11	Friedler et al. "Development of A Functional Backbone Cyclic Mimetic of the HIV-1 Tat Arginine-Rich Motif", The Journal of Biological Chemistry, 275(31): 23783-23789, 2000.			
	12	Melchior et al. "Inhibition of Nuclear Protein Import by Nonhydrolyzable Analogues of GTP and Identification of the Small GTPase Ran/TC4 as An Essential Transport Factor", The Journal of Cell Biology, 123(6): 1649-1659, 1993.			
	13	Lundberg et al. "Positively Charged DNA-Binding Proteins Cause Apparent Cell Membrane Translocation, Biochemical and Biophysical Research Communications, 291: 367-371, 2002.			
	14	Skrzypek et al. "Targeting of the Yersinia Pestis YopM Protein Into HeLa Cells and Intracellular Trafficking to the Nucleus", Molecular Microbiology, 30(5): 1051-1065, 1998.			
	15	Elliott et al. "Intercellular Trafficking and Protein Delivery by A Herpesvirus Structural Protein", Cell, 88: 223-233, 1997.			


Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

PTO/SB/08b (08-03)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Complete if Known

Application Number	10/508,959
Filing Date	August 16, 2005
First Named Inventor	Chaim GILON et al
Group Art Unit	1656
Examiner Name	DESAI, ANAND U

Sheet	2	Of	3	Attorney Docket Number	28557
-------	---	----	---	------------------------	-------

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	Bayer et al. "Effect of Bafilomycin A1 and Nocodazole on Endocytic Transport in HeLa Cells: Implications for Viral Uncoating and Infection", Journal of Virology, 72(12): 9645-9655, 1998.	
	17	Catizone et al. "Non-Specific Pinocytosis by Human Endothelial Cells Cultured as Multicellular Aggregates: Uptake of Lucifer Yellow and Horse Radish Peroxidase", Cellular and Molecular Biology, 42(8): 1229-1242, 1996.	
	18	Rossi et al. "Structural Analysis of the Substoichiometric and Stoichiometric Microtubule-Inhibiting Biphenyl Analogues of Colchicine", Biochemistry, 35: 3286-3289, 1996.	
	19	Suzuki et al. "Possible Existence of Common Internalization Mechanisms Among Arginine-Rich Peptides", The Journal of Biological Chemistry, 277(4): 2437-2443, 2002.	
	20	Polyakov et al. "Novel Tat-Peptide Chelates for Direct Transduction of Technetium-99m and Rhenium Into Human Cells for Imaging and Radiotherapy", Bioconjugate Chemistry, 11:762-771, 2000.	
	21	Plank et al. "Application of Membrane-Active Peptides for Drug and Gene Delivery Across Cellular Membranes", Advanced Drug Delivery Reviews, 34: 21-35, 1998.	
	22	Friedler et al. "Identification of A Nuclear Transport Inhibitory Signal (NTIS) in the Basic Domain of HIV-1 Vif Protein", Journal of Molecular Biology, 289: 431-437, 1999.	
	23	Karni et al. "A Peptide Derived From the N-Terminal Region of HIV-1 Vpr Promotes Nuclear Import in Permeabilized Cells: Elucidation of the NLS Region of the Vpr", FEBS Letters, 429: 421-425, 1998.	
	24	Efthymiadis et al. "The HIV-1 Tat Nuclear Localization Sequence Confers Novel Nuclear Import Properties", The Journal of Biological Chemistry, 273(3): 1623-1628, 1998.	
	25	Brinkmann et al. "High-Level Expression of Recombinant Genes in Escherichia Coli Is Dependent on the Availability of the DNA-Y Gene Product", Gene, 85: 109-114, 1989.	
	26	Kane "Effects of Rare Codon Clusters on High-Level Expression of Heterologous Proteins in Escherichia Coli", Current Opinion in Biotechnology, 6: 494-500, 1995.	
	27	Brisson et al. "Expression of A bacterial Gene in Plants by Using A Viral Vector", Nature, 310: 511-514, 1984.	
	28	Coruzzi et al. "Tissue-Specific and Light-Regulated Expression of A Pea Nuclear Gene Encoding the Small Subunit of Ribulose-1,5-Bisphosphate Carboxylase", The EMBO Journal, 3(8): 1671-1679, 1984.	
	29	Fingl et al. "General Principles", The Pharmacological Basis of Therapeutics, Sec.I(Chap.1): 1-46, 1975.	


Signature	Considered
-----------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/508,959	
			Filing Date	August 16, 2005	
			First Named Inventor	Chaim GILON et al	
			Group Art Unit	1656	
			Examiner Name	DESAI, ANAND U	
Sheet	3	Of	3	Attorney Docket Number	28557
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	30	Forseen et al. "Identification and Relationship of HER-2/Neu Overexpression to Short-Term Mortality in Primary Malignant Brain Tumors", Anticancer Research, 22: 1599-1602, 2002.			
	31	Gardella et al. "Expression of Human Parathyroid Hormone-(1-84) in Escherichia Coli as A Factor X-Cleavable Fusion Protein", The Journal of Biological Chemistry, 265(26): 15854-15859, 1990.			
	32	Goldfarb et al. "Synthetic Peptides as Nuclear Localization Signals", Nature, 322: 641-644, 1986.			
	33	Graessmann et al. "Microinjection of Tissue Culture Cells", Methods in Enzymology, 101(Chap.30): 482-492, 1983.			
	34	Gurley et al. "Upstream Sequences Required for Efficient Expression of A Soybean Heat Shock Gene", Molecular and Cellular Biology, 6(2): 559-565, 1986.			
	35	Hutvagner et al. "RNAi: Nature Abhors A Double-Strand", Current Opinion in Genetics & Development, 12: 225-232, 2002.			
	36	Louis et al. "Genetic Basis of Neurological Tumours", Baillieres Clinical Neurology, 3(2/Chap.7): 335-352, 1994.			
	37	Merrifield "Solid Phase Peptide Synthesis. I. The Synthesis of A Tetrapeptide", Journal of the American Chemical Society, 85: 2149-2154, 1963.			
	38	Gerard "Purification of Glycoproteins", Methods in Enzymology, 182(Chap.40): 529-539, 1990.			
	39	Amos et al. "HLA Typing", Transplantation Immunology, Chap.105: 797-804,			
	40	Sanghvi "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides", Antisense Research and Applications, CRC Press, Chap.15: 273-288, 1993.			
	41	Studier et al. "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes", 'Gene Expression Technology', Methods in Enzymology, 185(Chap.6): 60-89, 1990.			
	42	Sulkowski "Purification of Proteins by IMAC", Trends in Biotechnology, 3(1): 1-7, 1985.			
	43	Takamatsu et al. "Expression of Bacterial Chloramphenicol Acetyltransferase Gene in Tobacco Plants Mediated by TMV-RNA", The EMBO Journal, 6(2): 307-311, 1987.			
	44	Rogers et al. "Gene Transfer in Plants: Production of Transformed Plants Using Ti Plasmid Vectors", Method for Plant Molecular Biology, Sec.VIII: Gene Transfer, Chap.26: 423-463, 1988.			

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.